News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. (ESPR) Announces Oral Presentation On ETC-1002 At 2013 Scientific Sessions Of The American Heart Association


11/12/2013 10:12:35 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that full results of the Phase 2 ETC-1002-006 clinical study in patients with hypercholesterolemia and a history of statin intolerance will be presented in an oral presentation session by principal investigator Paul D. Thompson, M.D., on November 18 at the 2013 Scientific Sessions of the American Heart Association in Dallas. Later in the day, the Company will webcast a briefing of the results.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES